These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [MMP-9 and TIMP-1 levels in the sputum of patients with chronic obstructive pulmonary disease and asthma].
    Author: Calikoğlu M, Unlü A, Tamer L, Ozgür E.
    Journal: Tuberk Toraks; 2006; 54(2):114-21. PubMed ID: 16924566.
    Abstract:
    Chronic obstructive pulmonary disease (COPD) and asthma are associated with morphological changes in airway and lung and metalloproteinases are tought to play a role in this destruction. The aim of this study is to compare the levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinases (TIMP)-1 in the airways of COPD and asthma patients in stable period. We measured MMP-9 and TIMP-1 levels in the induced sputum of 20 asthma, 22 COPD patients in stable period and 15 healthy controls. MMP-9 and TIMP-1 levels were measured by using ELISA kits. MMP-9 and TIMP-1 levels were higher in patient groups than the controls. In COPD patients MMP-9 and TIMP-1 were significantly higher than the controls (respectively; p= 0.0001, p= 0.0001). Similarly, in asthma patients MMP-9 and TIMP-1 levels were higher than the controls (respectively; p= 0.005, p= 0.002). However, while there were no significant difference in MMP-9 levels between the patient groups (p= 0.29), TIMP-1 levels were significantly higher in COPD patients (96.2 +/- 58.2 versus 52.8 +/- 52 microg/mg protein, respectively, p= 0.0001). Atopic asthma patients TIMP-1 levels were slightly higher than non-atopic asthma patients (p> 0.05). There was no significant correlation between FEV(1) and MMP-9 or TIMP-1 levels in all groups. Although known pathogenetic differences in COPD and asthma, the increases in protease-antiprotease levels in both two patient groups may be associated with bronchial and parenchimal morphological changes. New treatment strategies which are focused on modulating of increased protease-antiprotease levels may be give a hope to patients with COPD and asthma.
    [Abstract] [Full Text] [Related] [New Search]